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Abstract
The spleen contains multiple subsets of myeloid and dendritic cells (DC). DC are important antigen presenting cells (APC) which induce and
control the adaptive immune response. They are cells specialized for antigen capture, processing and presentation to naı¨ve T cells. However,
DC are a heterogeneous population and each subset differs subtly in phenotype, function and location. Similarly, myeloid cell subsets can be
distinguished which can also play an important role in the regulation of immunity. This review aims to characterize splenic subsets of DC and
myeloid cells to better understand their individual roles in the immune response.
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Introduction
The spleen is a secondary lymphoid organ specialized for filtering
blood-borne antigens and removal of old or damaged erythrocytes. It
comprises two morphologically and functionally distinct compart-
ments (Fig. 1). The red pulp comprises an extensive network of cords
containing venous sinuses that act as filters to trap old or damage
erythrocytes that are phagocytosed by red pulp macrophages [1].
The white pulp is involved mainly with initiation of immune responses
against blood-borne antigens and pathogens. It comprises three
regions: the T cell zone or periarteriolar sheath (PALS), B cell follicles,
and the marginal zone [2]. The PALS is further divided into inner
PALS comprising mainly CD4+ T cells, some CD8+ T cells, interdigitat-
ing DC and migrating B cells. The outer PALS contains macrophages
[3]. B cell follicles are continuous with PALS and comprise B cells,
CD4+ T cells and follicular DC which have a distinct mesenchymal
origin [3]. The marginal zone is strategically situated at the interface
of the red pulp and PALS for screening blood-borne antigens and
pathogens. It contains a large reservoir of resident cells that partici-
pate in mounting an adaptive response against blood-borne antigens.
Several common subsets of DC in spleen have been well character-
ized, along with a number of distinct macrophage/monocyte cell
types. Other DC subsets are less well known. The functional impor-
tance of all subsets of DC and macrophages/monocytes in spleen is
still under investigation in terms of their comparative roles in antigen
presentation.
Common DC subsets in murine spleen
While DC are the most efficient APC in the immune system, with
unique ability to activate naı¨ve T cells, they are closely aligned with
myeloid cell types which can also function as APC. Multiple subsets
have been identified in both humans and mice [4, 5]. However, DC
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are unique in that they are capable of antigen uptake, processing and
presentation to naı¨ve T cells. They are a heterogeneous class of cells
with subtypes differing in tissue location, migratory pathway, cell sur-
face marker expression, immunological function and dependence on
infections or inflammatory stimuli for their generation [4]. They are
widely distributed throughout the body and distinct subsets have
been described in spleen, mucosa, intestine and epidermal tissue [4].
Some DC have been classified as migratory and these appear to sur-
vey the environment by constant uptake of tissue antigens. In the
presence of pathogen-related ‘danger signals’, they mature and
migrate to lymph nodes (LN) to present antigens to T cells [6]. In
contrast, lymphoid tissue-resident DC do not migrate, but take up and
present incoming antigen to T cells [6].
While the first observation of murine spleen DC was reported
by Steinman in 1973 [7], tools to isolate and study the population
in detail were not available until 1982 when the first DC-specific
monoclonal antibody was isolated [7, 8]. Now with multiple anti-
bodies and high-speed flow cytometry, the isolation and character-
ization of splenic DC is a common procedure. Conventional DC
(cDC) represent the main DC subset in spleen and have been fur-
ther classified into CD8a+ and CD8a subsets. CD8a+ cDC are phe-
notypically distinct as CD11c+CD11bCD8a+MHCII+B220 cells,
whereas CD8a cDC are CD11c+CD11b+CD8MHCII+B220 cells
[9] (Table 1). These subsets differ in immune function, including
cytokine production and ability to cross-present antigen [10]. The
mechanism of cross-presentation is considered in a later section on
Fig. 1 Compartmentalization of antigen presenting cells (APC) within splenic red and white pulp regions. Both CD8+cDC and white pulp macrophages
(WPM) lie in the T cell zone, whereas marginal-zone metallophilic macrophages (MMM), marginal-zone macrophages (MZM) and CD8 cDC lie
within the marginal zone. Red pulp macrophages (RMP) are localized in the red pulp. The tentative location of L-DC within the red pulp region is
based on experimental verification of high accessibility for blood-borne antigen compared with other DC subsets.
Table 1 The phenotype and T cell activation capacity of dendritic and myeloid subsets in murine spleen
Subset Phenotype
T cell activation*
Th Tc Tc:CP
CD8+ cDC CD11bCD11chiMHCII+CD8+Ly6CLy6G ++ +++ +++
CD8 cDC CD11bloCD11chiMHCII+CD8Ly6CLy6G +++ +++ +
pDC CD11bCD11c+MHCIIloCD8+/Ly6ChiLy6G + + +
Tip-DC CD11bhiCD11cinterMHCII+MAC-3+ ++ ++ 
L-DC CD11bhiCD11cloMHCIICD8Ly6CLy6G  + +++
Mo-DC CD11bhiCD172a+Ly6CLy6GF4/80+CD24+CD115DC-SIGN+ +++ +++ +++
Inflammatory monocytes CD11bhiCD11cMHCIICD8Ly6ChiLy6GF4/80+CD115+DC-SIGN   
Macrophages CD11bhiCD11cMHCIICD8Ly6CloLy6GF4/80+  + +
Neutrophils CD11bhiCD11cMHCIICD8Ly6C+Ly6G+F4/80  + +
*Th, helper T cell; Tc, cytotoxic T cell; Tc:CP, Tc cross-primed.
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the role of DC in antigen presentation. It has been proposed that
CD8a+ cDC play a role in the maintenance of tolerance to self-anti-
gens, consistent with their close proximity to T cells in the resting
state, and their notable capability for cross-presentation [11, 12].
CD8a+ cDC are also the predominant producer of IL-12, important
for CD8+ T cell proliferation [4]. In addition, they have recently been
described as a major producer of IFN-k in response Toll-like recep-
tor (TLR) 3 stimulation with double-stranded RNA [13]. In contrast,
CD8a cDC have weaker cross-priming ability and are mainly local-
ized in the marginal zone of spleen [11]. Upon stimulation with
lipopolysaccharides, CD8a cDC migrate to T cell areas and secrete
inflammatory chemokines [11]. The primary role of CD8a cDC,
however, still remains unclear [5].
Another common DC subset in spleen is the plasmacytoid DC
(pDC). Their history dates back to the first study on interferon and its
role in viral interference [14]. Numerous groups over 50 years have
investigated and identified a subset of cells, specialized for production
of interferon in viral infection [15]. However, over time each group
named the subset differently, e.g. natural IFN producing cells [16],
plasmacytoid T cells [17], plasmacytoid monocytes [18] and DC2
[19]. It was only in 1999 that it was determined that natural interferon
producing cells were found to a DC subset, namely the pDC [18, 20].
Plasmacytoid DC exist as a plasmacytoid pre-DC (p-pre-DC) in the
steady-state. They are relatively long-lived, circulating cells, which
produce high levels of type I interferon after stimulation with viral or
other microbial agents [21]. Plasmacytoid DC like cDC have been
described to arise from common dendritic progenitors (CDP) [22].
Inflammatory stimuli initiate the conversion of p-pre-DC into pDC,
and the production of type I interferons which enhance the function
of NK cells, B cells, T cells and DC during antiviral responses. Subse-
quently, pDC differentiate to give the CD8+CD205 DC subset, distinct
from CD8+ cDC that also regulate T cell function [23]. Plasmacytoid
DC are mainly distinguished by their CD11cloCD11bB220+ pheno-
type and production of type I interferons in response to TLR7 and
TLR9 signalling [6, 24] (Table 1).
DC represent a loosely defined class of cells either detectable
in spleen, or derived in vitro from myeloid precursors. Monocyte-
derived DC (mo-DC) represent a distinct subset derived from
monocytes in the presence of inflammatory factors like GM-CSF
and TNF-a [25, 26]. They can be induced by in vitro culture of
monocytes, and have also been demonstrated in vivo when inflam-
matory states lead to the exit of monocytes into tissue from blood
with induction of DC properties [25–27]. Until recently it has been
difficult to distinguish mo-DC from cDC in vivo using the common
markers of DC. They have a distinct phenotype as CD11b+CD11clo
F4/80loCD172a+MHC-II+Gr1CD115 cells (Table 1), distinguishing
them from both cDC and macrophages/monocytes. Recently DC-
SIGN/CD209 was identified as a specific marker of in vivo and
in vitro derived mo-DC [28]. They also demonstrate comparable
antigen presenting function to cDC, being capable of cross-presen-
tation to CD8+ T cells [29]. However, mo-DC only develop under
inflammatory conditions, commonly by LPS stimulation in vitro, or
by in vitro culture of myeloid precursors or monocytes with
inflammatory factors like GM-CSF and TNF-a.
TNF/iNOS-producing DC (TipDC) can also be identified in spleen.
Inflammatory stimuli appear to recruit circulating CD115+Ly6-
ChiCCR2+ inflammatory monocytes from blood into spleen and lymph
nodes where they differentiate to give TipDC [30, 31]. TipDC can be
distinguished from steady-state cDC on the basis of their unique
phenotype as CD11bhiCD11cinterMAC-3hiMHCII+ cells [32] (Table 1).
In general, TipDC secrete high levels of TNF-a and nitric oxide to
induce clearance of microbes from tissues.
Regulatory DC (DCreg) are also characterized by a common mye-
loid CD11c/loCD11b+MHCII/lo phenotype with ability to suppress
CD4+ T cell activity [33]. Some DCreg have also been found to induce
the differentiation of T helper (h)1 cells into regulatory T cells (Treg)
through production of IL-10 and TNF-b [34]. Subsequently, Tregs can
suppress CD4+ T cell proliferation through direct contact [34]. The in
vivo counterpart of DCregs has been reported [35, 36], although
these cells did not induce the formation of Tregs. Instead, suppres-
sion of CD4+ T cells was mediated by DCreg secretion of high levels
of nitric oxide (NO). Indeed, the DCreg cell type is still poorly defined
and likely represents a heterogeneous class of cells, some of which
derive by further differentiation of mature DC.
Common macrophage/monocyte
subsets in murine spleen
Monocytes are phagocytic cells of the myeloid lineage present in
several organs including bone marrow (BM), blood and spleen. Dur-
ing inflammation, they are recruited into bloodstream and tissues.
Monocytes develop in BM from macrophage/dendritic cell progenitors
(MDP) [37], and continuously migrate into blood by a CX3CL1-driven
mechanism [30]. When blood monocytes enter tissues they termi-
nally differentiate to give macrophages. Monocyte-derived DC may
also develop in lymphoid sites under inflammation induced by patho-
gen invasion [38]. Monocytes are distinct from granulocytes by their
F4/80loCD115+ phenotype and from lymphocytes by CD11bhiCD11c
expression [30]. In general, two subsets of monocytes can be
identified in blood: the classical CD115+Ly6Chi inflammatory mono-
cyte and the non-classical CD115+Ly6Clo resident monocyte [30].
Inflammatory monocytes home to sites of infection where they
differentiate to give TipDC [39], whereas resident monocytes home to
non-inflammatory sites and are thought to be precursors of macro-
phages resident in steady-state normal tissues like liver and spleen
[39]. The current model is that monocytes either terminally differenti-
ate to give macrophages, or become TipDC upon entry into tissues.
However, Swirski and coworkers recently identified a reservoir of
undifferentiated monocytes resident in spleen which resemble classi-
cal blood monocytes phenotypically, morphologically and transcrip-
tomically [40]. Upon inflammation, both these and resident
monocytes were mobilized from spleen to sites of inflammation. Clas-
sical monocytes from spleen were involved in clearing damaged
tissues, while resident monocytes promoted wound healing [40]. In
addition to this, spleen was able to deploy large numbers of mono-
cytes to a site of injury faster than BM [40]. Hence, the deployment of
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a reservoir of splenic monocytes has been hypothesized as a mecha-
nism facilitating a faster immune response.
Four subsets of macrophages have been described in spleen.
Two of these are located within the marginal zone; namely, mar-
ginal-zone metallophilic macrophages (MMM) and marginal-zone
macrophages (MZM) [3]. MMM can be visualized by staining with
the MOMA-1 monoclonal antibody, and localize near the PALS and
the B cell follicles [3]. While the functional potential of MMM has
not been completely elucidated, they appear to concentrate blood-
borne pathogens in the marginal zone via SIGLEC1 that interacts
with sialic-acid residues on pathogens [3]. Subsequently, clearance
of pathogens occurs through SIGLEC- and LPS-mediated phagocy-
tosis. The MZM are located closer to the red pulp and are charac-
terized by SIGNR1 expression [3]. MZM express a number of
pattern recognition receptors like TLR, type 1 scavenger receptor,
MARCO and the C-type lectin, SIGNR1, all of which play an impor-
tant role in the clearance of microorganism [41]. SIGNR1 efficiently
binds polysaccharide antigen on microorganisms like Mycobacte-
rium tuberculosis [41], and can also bind antigens expressed on
viruses [42], so emphasizing a role for MZM in viral clearance. In
contrast, MARCO expressed by MMM mainly binds antigen pre-
sented on pathogenic bacteria like Escherichia coli and Staphylo-
coccus aureus [43]. The tangible body macrophages within the
splenic white pulp can be distinguished from other macrophages
by expression of CD68 (CD11bF4/80CD68+) [44] (Table 1), and
their involvement in the phagocytosis of apoptotic B cells generated
during germinal centre reactions. The red pulp macrophages have
distinct F4/80 marker expression (CD11b+F4/80+CD68+), distin-
guishing them from MMM, MZM and tangible body macrophages,
all of which are F4/80 [44] (Table 1). Red pulp macrophages are
involved in the clearance of old or damaged RBC and the recycling
of heme groups.
Delineation of DC progenitors
Haematopoiesis occurs in BM where haematopoietic stem cells
(HSC) give rise to multipotent progenitors (MPP), which in turn
generate a range of lineage progenitor termed CLP (common
lymphoid progenitors) and CMP (common myeloid progenitors).
CLP give rise to a range of cells including NK (natural killer) cells,
and pro-T and pro-B cells that develop to give T and B cells
respectively. The CMP is thought to be a direct precursor of MDP
[45] that in turn generate CDP [37, 46–48]. Recent studies claims
that MDP generate cDC and monocytes which in turn develop to
give macrophages in tissues. The downstream CDP exclusively
generates cDC and pDC [37, 47]. However, there is still some
uncertainty over the relationship between these subsets, and partic-
ularly between CMP and MDP with CDP. MDP are a progenitor of
cDC as they can replenish splenic DC without formation of a mono-
cytic intermediate [47]. These experiments utilized BM chimaeras
generated by reconstitution of lethally irradiated wild-type mice with
BM from CD11c-diphtheria toxin (DTx) mice. Irradiation depleted
MDP from the host, whereas DTx treatment depleted macrophages
and DC from donor BM. However, it is still questionable whether
the replenishment of splenic DC occurred from MDP in donor BM
or from host monocytes under the inflammatory state.
While monocytes and p-pre-DC exit BM and enter blood as
mature cells, cDC leave BM and enter blood as pre-cDC precursors
that further differentiate and divide in spleen and other lymphoid tis-
sues [49]. There is also evidence that CD11c+MHCIILy6C+B220+
precursors exist in BM, which can give rise to pDC on adoptive trans-
fer [45]. The B220 variant of this CD11c+MHCIILy6C+ precursor
also gives rise to CD8a cDC [38]. In blood, distinct precursors for
cDC and pDC have been described as CD11cinterCD11b+B220 and
CD11cloCD11bB220hi cells respectively [46]. More recently, an
immediate precursor of cDC (pre-cDC) with a CD11c+CD43+SIRP-a+
phenotype and restricted cDC lineage potential was identified in
spleen, blood and BM [37, 49]. Pre-cDC are clearly distinct from
monocytes based on phenotype, morphology and immune function
as CD11cinterCD11bloF4/80loSIRP-ainter cells, while monocytes are
clearly distinct as CD11cCD11bhiF4/80hiSIRP-ainter cells [49]. Pre-
cDC also differ from monocytes in that the latter can differentiate in
response to M-CSF in culture [49]. Plasmacytoid DC develop from
CD11cloB220+ circulating immediate precursors (p-pre-DC) in blood
that lodge in spleen under inflammatory conditions to produce pDC
[46].
Role of DC in antigen presentation
Dendritic cells constantly endocytose antigens from the environ-
ment for presentation to T cells. Exogenous antigens are phagocy-
tosed or pinocytosed by DC, processed and presented on MHC-II
to CD4+ T cells. Lysosome-containing proteolytic enzymes fuse with
phagosomes carrying exogenous antigens to cleave antigen into
peptides. Newly synthesized MHC-II molecules are delivered by
vesicular transport to phagolysosomes containing peptides.
Peptides are then loaded on to MHC-II molecules for delivery to the
cell membrane and subsequent presentation to CD4+ T cells [50].
Activated CD4+ T cells differentiate to become effector T cells that
produce cytokines and activate monocytes to control infection. By
contrast, antigens produced endogenously by infected cells, or
defective ribosomal products, are tagged with ubiquitin for
destruction in the cytoplasm [51]. Ubiqitinated proteins are then
proteolytically cleaved into peptides. The transporter associated with
antigen processing (TAP) selectively allows peptides to enter the
endoplasmic reticulum (ER) where they are loaded on to MHC-I
molecules [50]. The MHC-I peptide complex is then transported to
the cell membrane within vesicles for antigen presentation to CD8+
cytotoxic T cells.
Some DC subsets can ‘cross-present’ exogenous antigens
acquired from dead tumour cells or virally infected cells on to
MHC-I molecules for presentation to CD8+ T cells [51, 52]. Cross-
presentation is a function largely restricted to CD8a+ cDC [53–56].
The exact mechanism by which exogenous antigens gain access to
newly synthesized MHC-I molecules remains under investigation.
One model involves ER-phagosome fusion. According to this model,
the presence of ER-derived components in phagosomes allows the
ER dislocon (a protein transporter), to participate in cross-presenta-
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tion at the phagosomal membrane by allowing translocation of pep-
tides from phagosomes into the cytosol [57]. Another model
involves peptides leaking from phagosomes into cytoplasm, or pep-
tides escaping into cytoplasm through rupture of the phagosomal
membrane, and becoming loaded on to MHC class I molecules out-
side the ER [58]. While other cell types like neutrophils [59] and
monocytes/macrophages [60, 61] are thought to function in cross-
presentation, these earlier reports remain unsubstantiated. Indeed,
definitive information on antigen presenting function is very depen-
dent on clear subset definition and isolation of pure subsets of
cells.
In vitro culture systems for generation
of dendritic and myeloid cells
Since DC are a rare cell type, in vitro culture systems that generate
large numbers of DC have therefore been popular for studies of func-
tion. Recently, two culture systems were described for generation of
DC with distinct function [62]. The first utilizes a cytokine cocktail of
granulocyte macrophage colony-stimulating factor (GM-CSF), tumour
necrosis factor (TNF)-a and interleukin (IL)-4 which stimulates mye-
loid precursors or monocytes to give mo-DC [62, 63]. The second
utilizes Flt3L, a cytokine which stimulates proliferation and differentia-
tion of BM-derived pre-DC to give cDC and pDC [62, 64, 65]. Indeed
IL-4 alone can induce blood monocytes to differentiate into immature
DC, and these cells have very similar phenotype to GM-CSF/IL-4
derived immature DC [66]. The GM-CSF/IL-4 culture system is an
attractive model for generating large numbers of DC. However, it pro-
duces specifically mo-DC which express CD11c, MHC-II and other
properties reflective of DC generated under inflammatory conditions.
They do not reflect steady-state cDC or immature DC. Evidence that
GM-CSF levels are low in resting mice but increase dramatically dur-
ing inflammation is consistent with cDC and pDC being present in
normal levels in spleens of GM-CSF/ mice [67].
FMS-related tyrosine kinase 3 ligand (Flt3-L) is a known prolif-
erative factor for DC [68], and Flt3-L supplemented BM cultures
have been shown to support production of both pDC and cDC [69].
Flt3-L has also been described as a growth factor for haematopoiet-
ic progenitors and mobilizes haematopoietic progenitors and stem
cells in vivo [70]. Flt3-L/ mutant mice demonstrate a lower DC
number in spleen, thymus and lymph nodes, emphasizing the
importance of Flt3L in DC development [71]. Recently, Naik et al.
[2005] showed that in vitro grown Flt3L-induced DC resemble with
the in vivo subsets of CD8a+ cDC and CD8a cDC in spleen. Phe-
notypes of CD24hiCD11bloCD172alo and CD24loCD11bhiCD172ahi
correspond with CD8a+ cDC and CD8a cDC present in murine
spleen [49, 65].
The Flt3L culture system contrasts with the GM-CSF/IL4 culture
system in that it generates steady-state DC instead of inflammatory
DC. Indeed, GM-CSF-induced DC and Flt3L-induced DC appear to
derive from distinct precursors [62]. When the CD11bhi
Ly6C+Ly6G monocyte population in BM was cultured with
GM-CSF, this gave rise to CD11bhiCD11cinterMac-3+MHC-II+ DC,
identical with TipDC [39], and no DC production was induced upon
culture with Flt3-L. Inflammatory monocytes in BM are precursors
of GM-CSF-induced DC, and GM-CSF-induced DC may be the in
vitro counterpart of TipDC. TipDC [32, 72] and mo-DC [26, 39]
populations have been shown to exist in vivo, but their full pheno-
type and function are not yet fully characterized. The conditions
under which they form, and their specific role in immunity com-
pared with cDC and pDC are yet to be distinguished.
As with DC, macrophages are present in low numbers in vivo,
which hampers in vivo studies and cell isolation. Macrophages can be
readily isolated from peritoneal cavity or lung by lavage. A culture
system was developed for increased cell production. This system is
very similar to the DC culture system, although different cytokines are
used to induce cell production. Macrophages differentiate from BM
progenitors upon addition of macrophage colony-stimulating factor
(M-CSF). Bone marrow-derived macrophages have been deemed
naı¨ve, reflecting steady-state macrophages, and these are phenotypi-
cally distinct from described subsets of inflammatory monocytes
which have the phenotype CD11b+CD11cMHC-IILy6ChiLy6GF4/
80+ [30, 39].
Long-term spleen cultures also
produce dendritic-like cells
A distinct dendritic-like cell type has been described in this laboratory
which is produced in vitro in murine splenic long-term cultures (LTC)
[73]. These ‘LTC-DC’ develop from spleen-derived progenitors
maintained within murine splenic stromal cultures [74]. Splenic
stroma maintained within LTC supports the continuous, but restricted
development of only this cell type without addition of cytokines like
GM-CSF, TNF-a, IL-4 or Flt3L. The continuous production of cells
within LTC suggests the presence of self-renewing progenitor or stem
cells within the stromal layer [75]. Recent studies have confirmed that
progenitors are maintained in LTC by endothelial-like cells unique to
spleen [76]. Haematopoietic cells form foci of proliferating cells
above the stroma, and continuously shed dendritic-like cells into the
medium from where they can be collected for study.
Non-adherent cells collected from LTC comprise a minor popula-
tion of small precursors/progenitors and a major population of large
cells that resemble immature splenic DC [77]. The non-adherent
small cells also represent a heterogeneous population of cells
expressing markers of haematopoietic progenitors like cKit, Sca-1
and Thy-1, with subsets of cells expressing CD11b, CD11c, CD117
and CD80, along with weak endocytic ability [77]. Indeed LTC-DC
production was achieved when the sorted small cell population was
cultured over a splenic stromal cell line STX3, derived from a LTC that
had lost haematopoietic cells with passage over time and hence dem-
onstrating the presence of self-renewing progenitors within the small
cell population [75]. In contrast, the large non-adherent LTC-DC
produced reflect a subset of immature myeloid splenic DC on the
basis of cell surface phenotype as CD11cloCD11bhiMHC-IIC-
D8aMHCI+CD80+CD86+ cells [77]. The absence of MHC-II or CD40
expression is a characteristic of these cells, also consistent with their
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derivation independently of pathogens or inflammatory cytokines. In
this respect, LTC-DC differ from MHC-II+CD40+ mature DC generated
from monocytes cultured in GM-CSF and IL-4 [62, 63], or cDC and
pDC derived from BM precursors cultured with Flt3L [62, 64, 65].
LTC-DC have now been shown to have cross-priming capability
[68]. When compared with freshly isolated CD11c+ cells from spleen,
LTC-DC are superior in activating CD8+ T cells in an antigen-specific
manner [68]. LTC-DC do not (or only weakly) activate CD4+ T cells,
consistent with their MHC-II/lo phenotype. In vitro derived LTC-DC
are highly efficient in cross-presentation, yet they have a distinct mar-
ker expression and function which distinguishes them from other DC
subsets described in spleen, or derived by cytokine-induced culture
of DC precursors [68].
Recently, an in vivo equivalent subset to LTC-DC, namely ‘L-DC’,
was identified in murine spleen based on its common phenotype,
its cross-priming capability and its inability to activate CD4+ T cells
[68]. L-DC are large cells, which express the same CD11clo
CD11bhiCD8MHC-II phenotype as LTC-DC (Table 1). The in vitro
cross-priming capability of L-DC was found to be comparable with
that of CD8+cDC [4, 68]. Like CD8+cDC, cross-presentation increases
after LPS activation [68]. Evidence of an in vivo cell type equivalent to
LTC-DC gives some physiological relevance to in vitro derived LTC-
DC and L-DC. The possibility that spleen contains an endogenously
derived APC with function specific to the spleen environment with
exposure to blood-borne pathogens is under further consideration.
Preliminary studies have also shown that L-DC are more poised
than other cDC or myeloid subsets in spleen for uptake of antigens in
blood. Hence, they have been tentatively located in the red pulp region
of spleen as shown in Figure 1. In vivo antigen priming prior to isola-
tion of APC subsets, followed by in vitro assays of T cell activation,
indicated that L-DC were superior to CD8a+ cDC and monocytes in
uptake and presentation of intravenous antigen [68]. L-DC have also
been shown capable of cross-priming CD8+ T cells in adoptive trans-
fer experiments [68], and may therefore represent an important
cross-presenting subset in spleen, especially under inflammatory
conditions. To date, they have been identified as cells within the
CD11bhiCD11cloCD8aMHC-IIFSChi splenic subset, which encom-
passes several subsets including those differing in expression of
Ly6C. Further characterization of L-DC is therefore underway, using a
broad range of dendritic, haematopoietic and myeloid markers to
more definitively characterize the L-DC phenotype and its relationship
with known splenic DC and myeloid cell subsets.
Localization and functional role of
dendritic and myeloid subsets in
spleen
Our hypothesis is that L-DC represent a spleen-endogenous, steady-
state DC. It will be imperative to review the splenic location of L-DC in
relation to other DC and myeloid cell types. In spleen, CD8a cDC are
strategically located within the marginal zone where they endocytose
antigen in blood carried from the terminating capillaries [3] (Fig. 1).
In contrast, CD8a+ cDC are located within the PALS in direct contact
with T cells [3] (Fig. 1) consistent with their cross-priming function
[4]. Others have shown that CD8a+ cDC also internalize apoptotic
cells in vivo [78, 79]. These CD8a+ cDC could also be derived from
CD8a cDC that have up-regulated CD8a expression upon migration
into PALS. On the basic of phenotype, L-DC are thought to localize
within the red pulp region in close proximity with blood vessels,
based on their superior ability to endocytose blood-borne antigen for
presentation to CD8+ T cells (Fig. 1).
While DC subsets within splenic lymphoid compartments have
been defined in terms of function and location, the complete pathway
for antigen uptake and presentation by DC still remains unclear. It is
not clear if CD8a cDC in the marginal zone endocytose blood-borne
antigen then transfer it to CD8a+ cDC in the PALS for effector T cell
activation, or whether CD8a cDC directly cross-prime T cells in the
white pulp [80]. Another possible explanation is that CD8a+ cDC
phagocytose dead/dying antigen-loaded CD8a cDC and then migrate
to the PALS. The antigen collection and presentation pathway in
spleen still remains an enigma, and any role for L-DC in antigen han-
dling in spleen is equally enigmatic.
Granulocytes in spleen are mainly localized in red pulp, but
some exist in transition within the marginal zone as blood-borne
cells flowing through marginal zone into red pulp [81]. In spleen,
the most common granulocyte is the neutrophil [81]. They are
key components of the inflammatory response, recruiting APC,
transporting antigen and controlling T cell expansion and differen-
tiation [59]. They can be distinguished from other leucocytes
based on their phenotype as CD11bhiCD11cLy6G+7/4+F4/80
MHCII cells [59, 82] (Table 1). Recently, it was shown that neu-
trophils from inflammatory peritoneal exudates could cross-prime
CD8+ T cells both in vivo and in vitro [59, 83]. These studies
demonstrated cross-priming capability under inflammatory condi-
tions which may not be reflective of steady-state neutrophils in
spleen [84]. The L-DC subset has already been investigated in
terms of its relationship with monocytes, macrophages and granu-
locytes. Absence of the marker Ly6G, clearly distinguishes them
from granulocytes. Absence of macrophage markers like MAC-3,
MOMA-1 and SIGNR1 distinguishes them from splenic macro-
phages (data in preparation). L-DC are clearly a distinct subset of
myeloid dendritic-like cells worthy of further investigation.
Conclusion
Spleen contains a diversity of DC and myeloid types which are both
phenotypically and functionally distinct. In addition to the well-defined
subsets, there are several smaller and less well-known subsets. The
current system of identifying subsets based on cell surface marker
phenotype obtained using flow cytometry has limitations, and their
function as an APC is another important consideration in terms of
lineage origin. The main cDC and myeloid subsets are replenished by
precursors from bone marrow that seed into the spleen. However,
spleen also produces an endogenously derived APC subset distinct
from previously described splenic DC. This L-DC subset is a function-
ally distinct APC which participates in induction of cytotoxic T cells
but not helper T cell responses. L-DC are thought to participate in
2616 ª 2012 The Authors
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immune responses against blood-borne antigen based on their
superior capability to endocytose and cross-present antigen by com-
parison with cDC.
L-DC phenotype reflects a myeloid dendritic-like cell based on
CD11b expression. It is clearly distinct from mo-DC in that it lacks
MHC-II expression. In addition, L-DC exist in the steady-state,
whereas mo-DC require addition inflammatory conditions and stimuli
such as LPS to develop. Indeed future studies will be required to
determine the lineage of L-DC in relation with other myeloid and DC
subsets.
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